Scottsdale, Arizona, Aug. 19, 2013 (GLOBE NEWSWIRE) -- Provista Diagnostics, Inc., a leading molecular diagnostics company focused on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, is pleased to announce that Mr. Joseph M. Eggler, Jr. has joined Provista as its Chief Commercial Officer. In this role, Mr. Egger will be responsible for executing and managing the Company's sales efforts, all commercial aspects of the business, reimbursement strategy and relationship management.
Mr. Eggler brings to Provista twenty two years of commercial pharmaceutical and diagnostic experience including strategic business planning, sales and marketing development; identifying and creating key industry partnerships; developing medical reimbursement programs; and, sales operations, training and commercial team leadership. He joins Provista from Prometheus Laboratories, a leading company in the development and commercialization of novel pharmaceutical and diagnostic products, where he spent the past 12 years.
President and Chief Executive Officer, Dr. David E. Reese commented, "Mr. Eggler's extensive knowledge and operational experience in the development and commercialization of pharmaceuticals and diagnostics will be critical in the transition of Provista to a full commercial organization. I am confident that Joe will add significant value to the company and I am delighted to welcome him to the team."
About Provista
Provista Diagnostics, Inc. is a privately held molecular diagnostics company focused on developing and commercializing through its dtect Dx platform, proprietary diagnostic, prognostic and predictive tests for cancers affecting women, including breast, endometrial and ovarian. Provista also offers diagnostic testing and clinical laboratory services to the pharmaceutical and biotechnology industries through Provista Diagnostics Reference Laboratory (PDxRL), a CLIA-accredited and GLP capable laboratory, licensed in 49 states to perform human clinical testing. More information about Provista is available at www.provistadx.com .
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
